A5069778340- Ovarian cancer diagnosis and treatment
- COVID-19 Clinical Research Studies
- Endometrial and Cervical Cancer Treatments
- SARS-CoV-2 and COVID-19 Research
- Blood transfusion and management
- Glycosylation and Glycoproteins Research
- Cervical Cancer and HPV Research
- Monoclonal and Polyclonal Antibodies Research
- Immune Cell Function and Interaction
- Galectins and Cancer Biology
- Immunotherapy and Immune Responses
- COVID-19 Impact on Reproduction
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Uterine Myomas and Treatments
- Reproductive System and Pregnancy
- Blood donation and transfusion practices
- Blood groups and transfusion
- Pain Management and Opioid Use
- SARS-CoV-2 detection and testing
- Intraperitoneal and Appendiceal Malignancies
- Estrogen and related hormone effects
- Cancer-related Molecular Pathways
- Hemoglobinopathies and Related Disorders
- Cardiac, Anesthesia and Surgical Outcomes
- Anesthesia and Pain Management
University of Wisconsin–Madison
2015-2025
UW Health University Hospital
2010-2024
University College London
2022
HealthONE Spalding Rehabilitation Hospital
2020
Highland Community College - Illinois
2011-2018
University of Tennessee at Knoxville
2018
Georgetown University
2017
University of Central Missouri
2015
Comprehensive Clinical Research
1988-2013
University of Alabama at Birmingham
2012
Abstract Human papillomaviruses (HPV) are associated with nearly all cervical cancers, 20% to 30% of head and neck cancers (HNC), other cancers. Because HNCs also arise in HPV-negative patients, this type cancer provides unique opportunities define similarities differences HPV-positive versus arising the same tissue. Here, we describe genome-wide expression profiling 84 HNCs, site-matched normal epithelial samples which used laser capture microdissection enrich for tumor-derived cells. This...
Abstract Background The mucin MUC16 and the glycosylphosphatidylinositol anchored glycoprotein mesothelin likely facilitate peritoneal metastasis of ovarian tumors. biochemical basis kinetics binding between these two glycoproteins are not clearly understood. Here we have addressed this deficit provide further evidence supporting role MUC16-mesothelin interaction in facilitating cell-cell under conditions that mimic environment. Results In study utilize recombinant-Fc tagged human to measure...
Cancer cells utilize a variety of mechanisms to evade immune detection and attack. Effective largely relies on the formation an synapse which requires close contact between their targets. Here, we show that MUC16, heavily glycosylated 3-5 million Da mucin expressed surface ovarian tumor cells, inhibits synapses NK Our results indicate MUC16-mediated inhibition is effective mechanism employed by tumors recognition.Expression low levels MUC16 strongly correlated with increased number...
Abstract Background MUC16 is a cell surface mucin expressed at high levels by epithelial ovarian tumors. Following proteolytic cleavage, (csMUC16) shed in the extracellular milieu and detected serum of cancer patients as tumor marker CA125. csMUC16 acts an adhesion molecule facilitates peritoneal metastasis Both sMUC16 also protect cells from cytotoxic responses natural killer (NK) cells. In previous study we demonstrated that binds to specific subset NK Here, identify csMUC16/sMUC16 binding...
The British standard 'BS30440: Validation Framework for the Use of AI in Healthcare' will be published second quarter 2023.[1][1] It details evidence required by technology developers to assess and validate products using artificial intelligence (AI) healthcare settings.
Summary The ovarian tumour marker MUC16 (CA125) inhibits the cytotoxic responses of human natural killer (NK) cells and down‐regulates CD16. Here we show that approximately 10% peripheral blood NK (PBNK) from epithelial cancer (EOC) patients are CD16 – CD56 br whereas 40% peritoneal fluid (PFNK) carry this phenotype, which is usually associated with lymph nodes or decidua. PBNK healthy donors exposed to PF a significant increase in population. This shift phenotype not caused by increased...
Ovarian cancer is particularly insidious in nature. Its ability to go undetected until late stages coupled with its non-descript signs and symptoms make it the seventh leading cause of related deaths women. Additionally, lack sensitive diagnostic tools resistance widely accepted chemotherapy regimens ovarian devastating patients families frustrating medical practitioners researchers. Here, we provide an in-depth review theories describing origin cancer, molecular factors that influence...
Abstract Background Liquid plasma (LP) is isolated from whole blood donations, never frozen, and can be immediately transfused. Its primary indication initial treatment of patients undergoing massive transfusion. To minimize wastage this resource, we expanded the use LP to include surgical routine transfusions. Methods Our medical record was queried for transfusions with at least one unit issued. Chart review identified indications transfusion (emergency use, or transfusion) assessed effects...
In Brief OBJECTIVE: To evaluate a quality improvement protocol for venous thromboembolism prevention in postoperative gynecologic cancer patients. METHODS: On January 1, 2006, we initiated universal of dual prophylaxis with sequential compression devices and three times daily heparin (or low molecular weight heparin) until discharge patients having major surgery. Patients both malignancy age over 60 years history prior clot) were discharged on 2 weeks anticoagulant. Before all given starting...
Humanized KS-interleukin-2 (huKS-IL2), an immunocytokine with specificity for epithelial cell adhesion molecule (EpCAM), has demonstrated favorable tolerability and immunologic activity as a single agent. Phase 1b study in patients EpCAM-positive advanced solid tumors to determine the maximum tolerated dose (MTD) safety profile of huKS-IL2 combination low-dose cyclophosphamide. Treatment consisted cyclophosphamide (300 mg/m2 on day 1), escalating doses (0.5–4.0 IV continuous infusion over 4...
SARS-CoV-2 and its associated disease, COVID-19, has infected over seven million people world-wide, including two in the United States. While many recover from virus uneventfully, a subset of patients will require hospital admission, some with intensive care needs intubation, mechanical ventilation. To date there is no cure vaccine available. Passive immunotherapy by transfusion convalescent plasma donated COVID-19 recovered might be an effective option to combat virus, especially if used...
Abstract Introduction The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is responsible for a worldwide pandemic. While the medical community understands mode of viral transmission, less known about how long shedding occurs once symptoms have resolved. Our objective was to determine SARS‐CoV‐2 remains detectable following self‐reporting symptom resolution. Methods This study approved by University Wisconsin Institutional Review Board. A cohort patients who...
SARS-CoV-2 and its associated disease, COVID-19, has infected over seven million people world-wide, including two in the United States. While many recover from virus uneventfully, a subset of patients will require hospital admission, some with intensive care needs intubation, mechanical ventilation. To date there is no cure vaccine available. Passive immunotherapy by transfusion convalescent plasma donated COVID-19 recovered might be an effective option to combat virus, especially if used...
The novel coronavirus, SARS-CoV-2 that causes COVID-19 has resulted in the death of nearly 4 million people within last 18 months. While preventive vaccination, and monoclonal antibody therapies have been rapidly developed deployed, early pandemic use convalescent plasma (CCP) was a common means passive immunization with theoretical risk antibody-dependent enhancement (ADE) viral infection. Though vaccines elicit strong protective immune response transfusion CCP high titers neutralization...